

AUTHORIZED BY: CPC Quality of Care Committee  
ISSUE DATE: June 2013  
CATEGORY: ACP/PCP Medications  
TITLE: **Ketorolac**

REVISION DATE: Sept 2018  
PAGE: 1 of 2

- 
- OtherNames:**
- Toradol
- Classifications:**
- Non-Steroidal Anti-Inflammatory, Analgesic
- Pharmacodynamics:**
- Ketorolac inhibits prostaglandin synthesis by blocking of the enzyme cyclo-oxygenase. This action is responsible for the analgesic and anti-inflammatory effects.
- Onset:**
- 10 minutes IV/IM
- Peak:**
- 2-3 hours
- Duration:**
- 6-8 hours
- Indications:**
- Treatment of mild to severe pain
- Contraindications:**
- NSAID or ibuprofen use within previous 6 hours
  - Allergy or sensitivity to ASA or NSAIDs
  - Patient on anticoagulation therapy
  - Current active bleeding
  - History of peptic ulcer disease or GI bleed
  - CVA or TBI in the previous 24 hours
  - If asthmatic, no prior use of ASA or other NSAID
  - Pregnant
  - Known renal impairment
- Precautions:**
- History of gastrointestinal tract irritations
  - Some NSAIDs can cause persistent urinary symptoms
  - Increased risk of GI bleeding when combined with alcohol
- AdverseReactions:**
- Cardiovascular: Hypertension, edema, vasodilation
  - IM administration: headache, dizziness, nausea, vomiting, sweating, drowsiness, injection site pain
  - The most serious associated risks involve the gastrointestinal system, including; bleeding, perforation and ulceration.
  - Asthmatic patients are at risk for severe hypersensitive reactions
- DrugInteractions**
- ACE Inhibitors: NSAIDs may diminish the antihypertensive effects of ACE Inhibitors
  - Furosemide and Diuretics: Ketorolac reduces the diuretic response of furosemide in normovolemic patients
  - Non-steroidal Anti-inflammatory Drugs (NSAIDs): Concomitant use of Ketorolac and NSAIDs increases the risk of GI side effects.

- Preparations:**
- 10 mg/ml
  - 30 mg/ml

- References:**
- Compendium of Pharmaceuticals and Specialties 2013
  - Ontario Provincial ALS Patient Care Standards, Version 4.5
  - Mosby's Paramedic Textbook, Revised Second Edition. 2001

**NOTE:** *The information contained herein does not supersede or negate the MoHLTC Provincial Medical Directives and should only serve as general information about the medication itself. For medication dosages, please refer to the current version of the Ontario Provincial ALS Patient Care Standards.*